Maya Lodish, MD

Maya Lodish, MD, MHSc, Selna L. Kaplan Chair, Distinguished Professorship in Pediatric Endocrinology/Diabetes, Professor of Pediatrics, Division Chief of Pediatric Endocrinology

Dr. Lodish completed her undergraduate degree at Dartmouth College, Hanover NH and she went on to Yale University School of Medicine. She completed her Internship & Residency in Pediatrics at the Johns Hopkins Hospital, Baltimore, MD. She pursued her Fellowship in Pediatric Endocrinology at the National Institutes of Health, Bethesda, MD. She completed a masters in clinical research at Duke University, Durham NC. While at the NIH, she served as Associate Research Physician and Director of the Fellowship in Pediatric Endocrinology. She led clinical research on endocrine tumors bridging collaborative endeavors between the National Cancer Institute (NCI), the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Child Health and Human Development (NICHD). She was the Primary Investigator for the protocol “A Clinical and genetic investigation of pituitary tumors and related hypothalamic disorders.” In 2018, Dr. Lodish joined the faculty at the University of California, San Francisco as the Selna L. Kaplan Chair, Distinguished Professorship in Pediatric Endocrinology/Diabetes, Professor of Pediatrics. Dr. Lodish’s role in the division is to mentor fellows, residents, and medical students in the intricacies of clinical research and quality improvement. She is working towards creating an interdisciplinary pediatric thyroid & endocrine oncology center at UCSF. Her research interests are in the endocrine-related complications faced by survivors of pediatric cancers, as well as in the genetic etiologies of pediatric neuroendocrine tumors. She plays a leading role in a number of studies to understand the pathophysiology and to improve the clinical care for pediatric patients with endocrine tumors including pheochromocytoma, Cushing syndrome, and thyroid cancer. At UCSF, Dr. Lodish is building a dynamic clinical research team in the field of endocrine oncology, fostering collaborations across campus including the neuro-oncology clinic, the cancer survivor multidisciplinary clinic, and the Pediatric Hereditary Cancer Clinic through the UCSF Cancer Genetics and Prevention Program. She has served as primary research mentor for a number of clinical fellows in pediatric endocrinology and is an active member of the scholarship oversight committee and program oversight committee at UCSF. Nationally, Dr. Lodish is a leader in the field of medical education as a member of the Clinical Education Committee of the Endocrine society from 2015-2018 and serves on the Pediatric Endocrine Society Education Committee.
2019 - Diversity, Equity, and Inclusion Champion Training, University of California
MHSc, 2012 - Clinical Research, Duke University
2009 - Fellowship in Pediatric Endocrinology, National Institutes of Health
2006 - Residency in Pediatrics, Johns Hopkins Hospital
MD, 2003 - , Yale University School of Medicine
BA, 1998 - Biochemistry and molecular biology, Dartmouth College
  1. Safety of growth hormone replacement in survivors of cancer and intra-cranial and pituitary tumours - A consensus statement.
  2. Neurofibromatosis Type 1 Has a Wide Spectrum of Growth Hormone Excess.
  3. How do clinicians integrate oral octreotide into their treatment plan for acromegaly?
  4. Trend of Diabetes-Related Hospital Admissions During the Transition Period From Adolescence to Adulthood in the State of California.
  5. Pheochromocytomas and paragangliomas.
  6. Cushing syndrome and glucocorticoids: T-cell lymphopenia, apoptosis, and rescue by IL-21.
  7. Pediatric Cushing's syndrome: greater risk of being overweight or obese after long-term remission and its predictive factors.
  8. The Association of ARMC5 with the Renin-Angiotensin-Aldosterone System, Blood Pressure, and Glycemia in African Americans.
  9. Rare Germline DICER1 Variants in Pediatric Patients With Cushing's Disease: What Is Their Role?
  10. Computerized Analysis of Brain MRI Parameter Dynamics in Young Patients With Cushing Syndrome-A Case-Control Study.
  11. Germline USP8 Mutation Associated With Pediatric Cushing Disease and Other Clinical Features: A New Syndrome.
  12. Cushing disease in a patient with nonbullous congenital ichthyosiform erythroderma: lessons in avoiding glucocorticoids in ichthyosis.
  13. ARMC 5 Variants and Risk of Hypertension in Blacks: MH- GRID Study.
  14. Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks.
  15. CRH stimulation improves 18F-FDG-PET detection of pituitary adenomas in Cushing's disease.
  16. Large Genomic Aberrations in Corticotropinomas Are Associated With Greater Aggressiveness.
  17. SGPL1 Deficiency: A Rare Cause of Primary Adrenal Insufficiency.
  18. Genetic Tumor Syndromes with Endocrine Involvement: A Compendium and an Update.
  19. Careful investigation of a rare disease: insights into multiple endocrine neoplasia type 2B.
  20. Aortic pulse wave velocity in children with Cushing syndrome: A window into a marker of early cardiovascular disease.
  21. Correction: Optical Imaging Technology: A Useful Tool to Identify Remission in Cushing Disease After Surgery.
  22. Optical Imaging Technology: A Useful Tool to Identify Remission in Cushing Disease After Surgery.
  23. Pheochromocytoma in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B.
  24. Multiple Endocrine Neoplasia Type 2B Presents Early in Childhood but Often Is Undiagnosed for Years.
  25. Mini-review of hair cortisol concentration for evaluation of Cushing syndrome.
  26. Xq26.3 Duplication in a Boy With Motor Delay and Low Muscle Tone Refines the X-Linked Acrogigantism Genetic Locus.
  27. Children with MEN1 gene mutations may present first (and at a young age) with Cushing disease.
  28. Cushing's Syndrome in Pediatrics: An Update.
  29. Irreversible Primary Amenorrhea Secondary to Uterine Damage and Premature Ovarian Failure in 2 Patients with Ewing Sarcoma.
  30. Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease.
  31. Incidence of Autoimmune and Related Disorders After Resolution of Endogenous Cushing Syndrome in Children.
  32. Postoperative Diabetes Insipidus and Hyponatremia in Children after Transsphenoidal Surgery for Adrenocorticotropin Hormone and Growth Hormone Secreting Adenomas.
  33. Earlier post-operative hypocortisolemia may predict durable remission from Cushing's disease.
  34. Decreased lymphocytes and increased risk for infection are common in endogenous pediatric Cushing syndrome.
  35. Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx )-related pheochromocytoma and paraganglioma in the pediatric population.
  36. Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
  37. Failure to Thrive in the Context of Carney Complex.
  38. Large pituitary gland with an expanding lesion in the context of neurofibromatosis 1.
  39. Potential utility of FLAIR in MRI-negative Cushing's disease.
  40. Harvey Cushing Treated the First Known Patient With Carney Complex.
  41. Somatic USP8 Gene Mutations Are a Common Cause of Pediatric Cushing Disease.
  42. Normalized Early Postoperative Cortisol and ACTH Values Predict Nonremission After Surgery for Cushing Disease.
  43. The Pediatric Medical Student Research Forum: Fostering Interest in Pediatric Research.
  44. Obesity and the diagnostic accuracy for primary aldosteronism.
  45. Cushing Disease in a patient with Multiple Endocrine Neoplasia type 2B.
  46. Bone mineral density in patients with inherited bone marrow failure syndromes.
  47. Corticotropinoma as a Component of Carney Complex.
  48. Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing's disease.
  49. Pediatric Cushing disease: disparities in disease severity and outcomes in the Hispanic and African-American populations.
  50. 3D Volumetric Measurements of GH Secreting Adenomas Correlate with Baseline Pituitary Function, Initial Surgery Success Rate, and Disease Control.
  51. Quantification of Thyroid Cancer and Multinodular Goiter Risk in the DICER1 Syndrome: A Family-Based Cohort Study.
  52. Circadian Plasma Cortisol Measurements Reflect Severity of Hypercortisolemia in Children with Different Etiologies of Endogenous Cushing Syndrome.
  53. Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas.
  54. Coagulation Profile in Patients with Different Etiologies for Cushing Syndrome: A Prospective Observational Study.
  55. Genetics of Adrenocortical Development and Tumors.
  56. Hair cortisol in the evaluation of Cushing syndrome.
  57. Case 1: Poor Growth With Presence of a Pituitary Lesion in an 11-year-old Boy.
  58. Delayed Diagnosis of Cushing's Disease in a Pediatric Patient due to Apparent Remission from Spontaneous Apoplexy.
  59. Effects of Glucocorticoids on Bone: What we can Learn from Pediatric Endogenous Cushing's Syndrome.
  60. Diurnal Plasma Cortisol Measurements Utility in Differentiating Various Etiologies of Endogenous Cushing Syndrome.
  61. Spontaneously Resolving Hyperreninemic Hypertension Caused by Accessory Renal Artery Stenosis in a 13-Year-Old Girl: A Case Report.
  62. Coagulation Profile Dynamics in Pediatric Patients with Cushing Syndrome: A Prospective, Observational Comparative Study.
  63. Growth hormone and risk for cardiac tumors in Carney complex.
  64. Bilateral Adrenal Hyperplasia as a Possible Mechanism for Hyperandrogenism in Women With Polycystic Ovary Syndrome.
  65. Screening for GPR101 defects in pediatric pituitary corticotropinomas.
  66. Attention Deficit Hyperactivity Disorder in Pediatric Patients with Pheochromocytoma and Paraganglioma.
  67. Use of 3-Dimensional Volumetric Modeling of Adrenal Gland Size in Patients with Primary Pigmented Nodular Adrenocortical Disease.
  68. Cases of Psychiatric Morbidity in Pediatric Patients After Remission of Cushing Syndrome.
  69. A genetic and molecular update on adrenocortical causes of Cushing syndrome.
  70. Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects.
  71. Pituitary gigantism: update on molecular biology and management.
  72. A novel AVPR2 splice site mutation leads to partial X-linked nephrogenic diabetes insipidus in two brothers.
  73. Pseudohypoaldosteronism type 1 due to novel variants of SCNN1B gene.
  74. Kidney Stones as an Underrecognized Clinical Sign in Pediatric Cushing Disease.
  75. Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.
  76. Pituitary abnormalities in patients with Fanconi anaemia.
  77. Lipoprotein Particles in Adolescents and Young Women With PCOS Provide Insights Into Their Cardiovascular Risk.
  78. Residual manifestations of hypercortisolemia following surgical treatment in a patient with Cushing syndrome.
  79. Facial Plethora: Modern Technology for Quantifying an Ancient Clinical Sign and Its Use in Cushing Syndrome.
  80. The ARMC5 gene shows extensive genetic variance in primary macronodular adrenocortical hyperplasia.
  81. Germline PRKACA amplification causes variable phenotypes that may depend on the extent of the genomic defect: molecular mechanisms and clinical presentations.
  82. Expanding the clinical and molecular characteristics of PIGT-CDG, a disorder of glycosylphosphatidylinositol anchors.
  83. Primary Aldosteronism and ARMC5 Variants.
  84. X-linked acrogigantism syndrome: clinical profile and therapeutic responses.
  85. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice.
  86. Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy.
  87. A gender-dependent analysis of Cushing's disease in childhood: pre- and postoperative follow-up.
  88. Cushing's syndrome in childhood: update on genetics, treatment, and outcomes.
  89. Endocrine disorders in Fanconi anemia: recommendations for screening and treatment.
  90. Ectopic adrenocorticotropic hormone and corticotropin-releasing hormone co-secreting tumors in children and adolescents causing cushing syndrome: a diagnostic dilemma and how to solve it.
  91. Is IGSF1 involved in human pituitary tumor formation?
  92. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation.
  93. Use of aromatase inhibitors in large cell calcifying sertoli cell tumors: effects on gynecomastia, growth velocity, and bone age.
  94. Not all glucocorticoid-induced obesity is the same: differences in adiposity among various diagnostic groups of Cushing syndrome.
  95. Germline PRKACA amplification leads to Cushing syndrome caused by 3 adrenocortical pathologic phenotypes.
  96. Post-operative growth is different in various forms of pediatric Cushing's syndrome.
  97. Death in pediatric Cushing syndrome is uncommon but still occurs.
  98. Vitamin B12 deficiency in an adolescent girl with polycystic ovarian syndrome.
  99. Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.
  100. Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation.
  101. Pituitary stalk lesion in a 13-year-old female.
  102. Skeletal maturation in children with Cushing syndrome is not consistently delayed: the role of corticotropin, obesity, and steroid hormones, and the effect of surgical cure.
  103. Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I.
  104. Differences in adiposity in Cushing syndrome caused by PRKAR1A mutations: clues for the role of cyclic AMP signaling in obesity and diagnostic implications.
  105. Racial disparities in pubertal development.
  106. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
  107. Multiple endocrine neoplasia type 2.
  108. Clinical review: kinase inhibitors: adverse effects related to the endocrine system.
  109. Bone mineral density in children and young adults with neurofibromatosis type 1.
  110. Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours.
  111. Recovery of the hypothalamic-pituitary-adrenal axis in children and adolescents after surgical cure of Cushing's disease.
  112. Known VDR polymorphisms are not associated with bone mineral density measures in pediatric Cushing disease.
  113. Lack of mutations in the gene coding for the hGR (NR3C1) in a pediatric patient with ACTH-secreting pituitary adenoma, absence of stigmata of Cushing's syndrome and unusual histologic features.
  114. (111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents.
  115. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
  116. The differential diagnosis of familial lentiginosis syndromes.
  117. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.
  118. Rare and unusual endocrine cancer syndromes with mutated genes.
  119. Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype.
  120. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.
  121. SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors.
  122. Endocrine side effects of broad-acting kinase inhibitors.
  123. Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl.
  124. Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes.
  125. Intrauterine growth retardation associated with precocious puberty and sertoli cell hyperplasia.
  126. Effects of Cushing disease on bone mineral density in a pediatric population.
  127. Pseudotumor cerebri after surgical remission of Cushing's disease.
  128. The growth hormone receptor (GHR) polymorphism in growth-retarded children with Cushing disease: lack of association with growth and measures of the somatotropic axis.
  129. Reversible posterior encephalopathy syndrome associated with micronodular adrenocortical disease and Cushing syndrome.
  130. An Intronic mutation is associated with prolactinoma in a young boy, decreased penetrance in his large family, and variable effects on MEN1 mRNA and protein.
  131. Blood pressure in pediatric patients with Cushing syndrome.
  132. Extensive and largely reversible ischemic cerebral infarctions in a prepubertal child with hypertension and Cushing disease.
  133. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
  134. Insulinoma and gastrinoma syndromes from a single intrapancreatic neuroendocrine tumor.
  135. GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis.
  136. Proper coronary vascular development and heart morphogenesis depend on interaction of GATA-4 with FOG cofactors.
  137. Use of altered specificity mutants to probe a specific protein-protein interaction in differentiation: the GATA-1:FOG complex.
  138. Autotransplantation of pancreatic islet cell fragments into the renal capsule prepared without collagenase.